Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00953446 · ClinicalTrials.gov registry record · NA
Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT00953446 is a NA study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT00953446, a NA study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to assess magnetic resonance imaging (MRI) as a tool to track tumor growth for renal cell carcinoma while participants are on clinical treatment therapy of sunitinib and AMG386. An MRI is a type of scan that uses powerful magnets to make clearer images or to focus on detailed medical information in the abdomen and pelvis. The imaging done for this study will use the arterial spin labeling (ASL) MRI technique that allows us to see blood flow changes which possibly may indicate changes in tumor growth. Participants will be on a clinical trial for the treatment.
Interventions
- PROCEDURE Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-06-15 |
| Est. Completion | 2011-09-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00953446
The ClinicalTrials.gov registry entry for NCT00953446 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging is the first listed.
NCT00953446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00953446 about?
NCT00953446 is a clinical study titled "Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma". The purpose of this study is to assess magnetic resonance imaging (MRI) as a tool to track tumor growth for renal cell carcinoma while participants are on clinical treatment therapy of sunitinib and AMG386. An MRI is a type of scan that uses powerful magnets to make clearer images or to focus on det...
What is the current status of trial NCT00953446?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2010-06-15. Estimated completion is 2011-09-13.
What interventions are being tested in trial NCT00953446?
The interventions under investigation include: Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT00953446?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.